OSUR

Business Context and Reporting Period

Company: OraSure Technologies, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2003
Business Overview: The company develops, manufactures, and markets oral specimen collection devices, diagnostic products (including in vitro diagnostic tests), and medical devices. Key products include the OraQuick rapid HIV-1 antibody test, Intercept oral fluid collection devices, and Histofreezer cryosurgical systems.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 17% to $18.2 million for the six months ended June 30, 2003, compared to $15.7 million in the prior year period. Quarterly revenue increased 21% to $9.6 million.
• Product Mix Shifts:
  • Infectious Disease Testing: Revenues surged 78% (six months) and 73% (quarterly) driven by the OraQuick rapid HIV-1 antibody test.
  • Cryosurgical Systems: Quarterly revenues jumped 73% due to initial sales of the OTC "Freeze Off" product to Medtech Holdings. However, professional market sales of Histofreezer declined.
  • Insurance Risk Assessment: Revenues declined 8% (six months) and 21% (quarterly) due to competitive pressure and the loss of a major customer (Lab One, Inc.) which stopped purchasing urine assays.
• Profitability: Despite revenue growth, the company reported a net loss of $1.6 million for the six months, an improvement from the $2.9 million loss in the prior year period. Operating loss narrowed to $1.7 million from $3.0 million.
• Expenses: Research and development expenses decreased 13% to $4.0 million. Sales and marketing expenses increased 14% to $5.0 million due to advertising for new products.

Guidance, Outlook, and Risks

• CDC Contract: The company received a $2 million purchase order from the Centers for Disease Control and Prevention (CDC) for 250,000 OraQuick devices. Most sales are expected to occur in the fourth quarter of 2003.
• Medtech Agreement: A five-year distribution agreement with Medtech Holdings for the OTC wart removal product includes minimum annual purchases. The company expects to ship the balance of the initial $2.0 million minimum purchase in the third quarter of 2003.
• Regulatory Approvals: The company is seeking FDA approval for OraQuick usage with venous whole blood, oral fluid, and plasma to penetrate the hospital market. It is also seeking approval for HIV-2 detection.
• Financial Covenants: The company's credit facility with Comerica Bank requires the achievement of positive net income for the year ending December 31, 2003, and each year thereafter. Failure to meet this could impact liquidity.
• Risks:
  • Loss of the Lab One customer is expected to negatively impact revenues by up to $1.5 million in 2003 and $2.0 million in 2004.
  • Potential cannibalization of OraSure device sales by the OraQuick test in the infectious disease market.
  • Inventory valuation risks due to expiration dates and demand forecasting for new products.

Investor Verification Checklist

• CDC Revenue Timing: Verify the actual shipment and revenue recognition schedule for the $2 million CDC order, as management expects most sales in Q4 2003.
• Profitability Covenant: Monitor the company's ability to achieve positive net income for the full year 2003 to comply with its credit facility covenants.
• Customer Concentration: Assess the impact of the loss of Lab One, Inc. and the reliance on Abbott Laboratories for OraQuick distribution (Abbott purchased 52% of OraQuick devices in the first six months).
• Inventory Levels: Review inventory turnover and potential write-offs, particularly for products with expiration dates and the new OraQuick launch.
• Regulatory Milestones: Track the status of FDA submissions for OraQuick's venous blood, oral fluid, and HIV-2 claims, which are critical for hospital market penetration.